• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 21st October 2010

Access to Orphan Drugs in the EU

Legislation in the EU provides incentives for the developmeng of drugs for rare diseases, known as orphan medicinal products (OMPs). At a recent conference, OHE’s Dr Mestre-Ferrandiz reported on OHE research that examines the impact of these measures as well…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
MartinaHEAD373_Dec2011

Legislation in the EU provides incentives for the developmeng of drugs for rare diseases, known as orphan medicinal products (OMPs). At a recent conference, OHE’s Dr Mestre-Ferrandiz reported on OHE research that examines the impact of these measures as well as whether and how pricing and reimbursement policies affect access in practice.

Martina Garau

Orphan drugs, or orphan medicinal products (OMPs), are meant to diagnose, prevent or treat life-threatening or debilitating diseases in small patient populations.  In the US, an orphan disease is defined as one affecting no more than an average of 7.5 per 10,000 people; in the EU, the number is 5 per 10,000.  Efforts to encourage the development of OMPs began with the Orphan Drug Act in the US in 1983, followed by the EU Regulation on Orphan Medicinal Products in 1999.  Both contain incentives meant to encourage development by providing tax credits and/or stipulating periods of market and/or data exclusivity.  Both also offer an accelerated approval processes.  The EU legislation also allows a single, EU-wide marketing authorisation for OMPs.

The incentives have made a difference. Between 2001 and 2009, 68 OMPs were approved for use in the EU; since 2006, nearly 12 OMPs have been approved, on average, every year.  This rate is expected to remain fairly constant going forward.

Encouraging development and speeding approval is very important, but that alone does not ensure that OMPs are available to patients.  Formal and informal policies and procedures for determining pricing and reimbursement (P&R) also affect access.  OHE’s Dr. Jorge Mestre-Ferrandiz recently presented the results of comparative research on these factors at the 9th Annual Pricing and Reimbursement Conference in late September.

The OHE study compares P&R policy for 43 OMPs across seven EU Member States: France, Germany, Italy, The Netherlands, Spain, Sweden and the UK.  In particular, the study examines: the standards of evidence and the criteria for P&R decisions, the availability of access before full licensing approval, and requirements for studies after the drug is available on the market.  Dr Mestre-Ferrandiz emphasised that OMPs present special challenges for evidence collection, both before and after licensing.  Because the patient population is small by definition, minimal epidemiologic and disease burden data are available, diagnostic systems are suboptimal, and very few health care professionals are trained in the diagnosis and treatment of each rare disease.

OHE’s research shows that requirements and practice vary substantially across the seven countries in the study.  For example, when access decisions are based primarily on clinical evidence, countries are flexible in their criteria and their approach, accepting lower risk-benefit ratios for OMPs than for other new medicines.  When a formal health technology assessment (HTA) process is required, however, evidence requirements are the same as for non-OMP drugs (except in The Netherlands).  Countries also vary with respect to pre-market access and requirements for post-launch studies.

Decisions based on HTA can affect P&R and, as a result, access to OMPs by patients.  In countries without formal HTA requirements, nearly all OMPs included in the OHE study were considered eligible for reimbursement.  In the UK, the Scottish HTA body has rejected some of these and/or recommended restricted use.  Sweden has the highest rate of rejection (almost 70% are not reimbursed).

OMPs account for a small portion of total drug spending, an average of 1.7 percent in 2007 in the top five EU countries.  Dr Mestre-Ferrandiz pointed out, however, that low spending levels will not necessarily protect OMPs from demands for more evidence.  Continuingly scarce health care resources may create demands for cost effectiveness evidence even for OMPs.  This would create serious challenges: OMPs are approved by the EMA on an accelerated basis, which means that data required for HTA are less likely to be available at that time than for other new medicines.  As noted above, collecting additional data, after approval, also can be problematic because of the nature of rare diseases.

To meet these challenges, Dr Mestre-Ferrandiz recommends greater cooperation across countries to develop a more robust evidence base for OMPs.  Data will need to be collected and research conducted across countries at the European and international levels.  Moreover, in order to ensure timely access to new OMPs, much of this research will need to be done after the drug appears on the market.  Finally, cooperation across stakeholders is essential; interactions involving the EMA, HTA bodies and sponsors early in the development process can help avoid delays by identifying potential evidence issues then and developing ways to address them.

Download Garau, M. and Mestre-Ferrandiz, J. (2009) Access mechanisms for orphan drugs: A comparative study of selected European countries. OHE Briefing. London: Office of Health Economics.

  • Health Technology Assessment…
  • Economics of Innovation
  • Innovation

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • June 2020

OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare

Read more
  • News
  • May 2020

Indication-Based Pricing: Are We All Onboard?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!